SRR13780263
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.560
- IL6_JAK_STAT3_SIGNALING+0.540
- INTERFERON_GAMMA_RESPONSE+0.540
- INFLAMMATORY_RESPONSE+0.480
- INTERFERON_ALPHA_RESPONSE+0.480
- TNFA_SIGNALING_VIA_NFKB+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- IL2_STAT5_SIGNALING+0.400
- HYPOXIA+0.370
- COAGULATION+0.360
Top 10 suppressed
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.520
- MITOTIC_SPINDLE-0.460
- MYC_TARGETS_V1-0.440
- DNA_REPAIR-0.390
- MYC_TARGETS_V2-0.260
- SPERMATOGENESIS-0.180
- PANCREAS_BETA_CELLS-0.120
- TGF_BETA_SIGNALING-0.110
- HEDGEHOG_SIGNALING-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_PQ6QEVE8 | Ganglioglioma | — | 0.915 |
| 2 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.898 |
| 3 | MDT-AP-0452 | Med | Medulloblastoma | 0.896 |
| 4 | MDT-AP-0410 | Med | Medulloblastoma | 0.894 |
| 5 | BS_HC5M8JTC | low-grade glioma | — | 0.890 |
| 6 | MDT-AP-2021 | Med | Medulloblastoma | 0.885 |
| 7 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.883 |
| 8 | GSM5359409 | — | — | 0.881 |
| 9 | SRR3147740 | — | — | 0.881 |
| 10 | BS_55JW3HFM | Ganglioglioma | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |